Daniel Calkins Sells 5,039 Shares of Verastem (NASDAQ:VSTM) Stock

Verastem, Inc. (NASDAQ:VSTM) CFO Daniel Calkins sold 5,039 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $7.16, for a total value of $36,079.24. Following the transaction, the chief financial officer owned 104,719 shares of the company’s stock, valued at $749,788.04. This trade represents a 4.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Daniel Calkins also recently made the following trade(s):

• On Wednesday, December 24th, Daniel Calkins sold 80 shares of Verastem stock. The stock was sold at an average price of $7.86, for a total transaction of $628.80.

Verastem Stock Down 2.8%

VSTM stock opened at $6.60 on Friday. The firm’s 50-day moving average is $8.66 and its two-hundred day moving average is $8.08. The company has a market capitalization of $440.75 million, a price-to-earnings ratio of -1.64 and a beta of 0.44. Verastem, Inc. has a 52 week low of $4.01 and a 52 week high of $11.24. The company has a current ratio of 2.58, a quick ratio of 2.55 and a debt-to-equity ratio of 2.06.

Verastem (NASDAQ:VSTM) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.84). The business had revenue of $11.24 million during the quarter, compared to analysts’ expectations of $5.76 million. On average, analysts forecast that Verastem, Inc. will post -3.02 earnings per share for the current fiscal year.

Analysts Set New Price Targets

VSTM has been the subject of several research reports. Royal Bank Of Canada set a $13.00 price objective on shares of Verastem and gave the company an “outperform” rating in a research report on Monday, October 20th. Cantor Fitzgerald raised shares of Verastem to a “strong-buy” rating in a research note on Thursday, October 30th. Mizuho set a $15.00 price target on shares of Verastem in a research report on Wednesday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Verastem in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut Verastem from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $14.29.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC lifted its stake in Verastem by 78.2% in the 1st quarter. AQR Capital Management LLC now owns 62,603 shares of the biopharmaceutical company’s stock worth $377,000 after acquiring an additional 27,477 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Verastem by 236.9% in the first quarter. Goldman Sachs Group Inc. now owns 756,402 shares of the biopharmaceutical company’s stock worth $4,561,000 after purchasing an additional 531,873 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Verastem by 32.8% during the first quarter. Rhumbline Advisers now owns 49,959 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 12,330 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in Verastem during the second quarter valued at approximately $643,000. Finally, Los Angeles Capital Management LLC acquired a new position in Verastem in the 2nd quarter valued at approximately $106,000. Hedge funds and other institutional investors own 88.37% of the company’s stock.

About Verastem

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.